Celltrion (KOSE:A068270) - Share price, News & Analysis

A068270 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	3/6
Financial Health	6/6
Dividends	3/6

A068270 Stock Overview

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea.

Rewards

Trading at 29.3% below our estimate of its fair value

Earnings are forecast to grow 14.67% per year

Earnings have grown 17.7% per year over the past 5 years

Risk Analysis

No risks detected for A068270 from our risk checks.

Celltrion Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celltrion
Historical stock prices
Current Share Price	₩141,000.00
52 Week High	₩294,607.84
52 Week Low	₩139,000.00
Beta	0.81
1 Month Change	-11.60%
3 Month Change	-10.48%
1 Year Change	-46.44%
3 Year Change	-14.90%
5 Year Change	70.85%
Change since IPO	1,264.28%

Shareholder Returns

	A068270	KR Biotechs	KR Market
7D	-2.8%	0.8%	3.2%
1Y	-46.4%	-38.0%	-14.6%

Return vs Industry: A068270 underperformed the KR Biotechs industry which returned -38% over the past year.

Return vs Market: A068270 underperformed the KR Market which returned -14.6% over the past year.

Price Volatility

Is A068270's price volatile compared to industry and market?
A068270 volatility
A068270 Average Weekly Movement	6.0%
Biotechs Industry Average Movement	6.6%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: A068270 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: A068270's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2002	2,072	Hyong-Gi Kim	https://www.celltrion.com

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial.

Celltrion Fundamentals Summary

How do Celltrion's earnings and revenue compare to its market cap?
A068270 fundamental statistics
Market Cap	₩19.58t
Earnings (TTM)	₩575.09b
Revenue (TTM)	₩1.91t

34.1x

P/E Ratio

10.2x

P/S Ratio

Is A068270 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A068270 income statement (TTM)
Revenue	₩1.91t
Cost of Revenue	₩810.18b
Gross Profit	₩1.10t
Other Expenses	₩526.33b
Earnings	₩575.09b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	4.14k
Gross Margin	57.62%
Net Profit Margin	30.08%
Debt/Equity Ratio	18.1%

How did A068270 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

18%

Payout Ratio

Valuation

Is Celltrion undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

29.3%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: A068270 (₩141000) is trading below our estimate of fair value (₩199507.45)

Significantly Below Fair Value: A068270 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: A068270 is poor value based on its PE Ratio (34.1x) compared to the KR Biotechs industry average (25.4x).

PE vs Market: A068270 is poor value based on its PE Ratio (34.1x) compared to the KR market (14.4x).

Price to Earnings Growth Ratio

PEG Ratio: A068270 is poor value based on its PEG Ratio (2.3x)

Price to Book Ratio

PB vs Industry: A068270 is overvalued based on its PB Ratio (5x) compared to the KR Biotechs industry average (3.3x).

Future Growth

How is Celltrion forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

14.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A068270's forecast earnings growth (14.7% per year) is above the savings rate (3.5%).

Earnings vs Market: A068270's earnings (14.7% per year) are forecast to grow slower than the KR market (14.8% per year).

High Growth Earnings: A068270's earnings are forecast to grow, but not significantly.

Revenue vs Market: A068270's revenue (13.5% per year) is forecast to grow faster than the KR market (9.6% per year).

High Growth Revenue: A068270's revenue (13.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A068270's Return on Equity is forecast to be low in 3 years time (16.5%).

Past Performance

How has Celltrion performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

17.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A068270 has high quality earnings.

Growing Profit Margin: A068270's current net profit margins (30.1%) are higher than last year (27.7%).

Past Earnings Growth Analysis

Earnings Trend: A068270's earnings have grown by 17.7% per year over the past 5 years.

Accelerating Growth: A068270's earnings growth over the past year (12.5%) is below its 5-year average (17.7% per year).

Earnings vs Industry: A068270 earnings growth over the past year (12.5%) underperformed the Biotechs industry 37.5%.

Return on Equity

High ROE: A068270's Return on Equity (14.5%) is considered low.

Financial Health

How is Celltrion's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: A068270's short term assets (₩3,076.9B) exceed its short term liabilities (₩1,210.5B).

Long Term Liabilities: A068270's short term assets (₩3,076.9B) exceed its long term liabilities (₩413.3B).

Debt to Equity History and Analysis

Debt Level: A068270 has more cash than its total debt.

Reducing Debt: A068270's debt to equity ratio has reduced from 30.9% to 18.1% over the past 5 years.

Debt Coverage: A068270's debt is well covered by operating cash flow (123.6%).

Interest Coverage: A068270's interest payments on its debt are well covered by EBIT (195.9x coverage).

Balance Sheet

Dividend

What is Celltrion current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

0.52%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A068270's dividend (0.52%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (0.84%).

High Dividend: A068270's dividend (0.52%) is low compared to the top 25% of dividend payers in the KR market (2.75%).

Stability and Growth of Payments

Stable Dividend: A068270's dividend payments have been volatile in the past 10 years.

Growing Dividend: A068270's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (17.8%), A068270's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (16.5%), A068270's dividend payments are well covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.2yrs

Average board tenure

CEO

Hyong-Gi Kim (56 yo)

no data

Tenure

Mr. Hyong-Gi Kim serves as Chief Executive Officer at Celltrion, Inc. Mr. Kim served as Vice President of Celltrion Pharm Inc. He served as Head of Strategy and Planning Team, Daewoo Motor Company. He serv...

Board Members

Experienced Board: A068270's board of directors are considered experienced (8.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/19 00:00
End of Day Share Price	2022/05/19 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31